Followers | 832 |
Posts | 119983 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
![](https://investorshub.advfn.com/uicon/14742.png?cb=1465058685)
Friday, September 30, 2022 4:02:26 PM
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-26-29-september-2022
Imbruvica (ibrutinib): new risk minimisation measures, including dose modifications, due to the increased risk for serious cardiac events
This DHPC aims to inform healthcare professionals about an increased risk of fatal and serious cardiac arrhythmias and cardiac failure with the use of ibrutinib.
...Patients with advanced age, Eastern Cooperative Oncology Group (ECOG) performance status >-2, or cardiac co-morbidities may be at greater risk of cardiac events including sudden fatal cardiac events.
The PRAC advises that a clinical evaluation of cardiac history and function should be performed before starting a treatment with ibrutinib. In patients with risk factors for cardiac events, benefits and risks should be assessed before initiating treatment with the medicine and alternative treatment may be considered. Patients should be carefully monitored during treatment for signs of deterioration of cardiac function and be clinically managed.
Ibrutinib should be withheld for any new onset or worsening of grade 2 cardiac failure or grade 3 cardiac arrhythmias. Treatment may be resumed as per new dose modification recommendations.
The DHPC for Imbruvica will be forwarded to EMA’s human medicines committee (CHMP). Following the CHMP decision, the DHPC will be disseminated to healthcare professionals by the marketing authorisation holder, according to an agreed communication plan, and published on the ‘Direct healthcare professional communications’ page and in national registers in EU Member States.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent ABBV News
- Tesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More News • IH Market News • 07/05/2024 12:13:34 PM
- AbbVie to Host Second-Quarter 2024 Earnings Conference Call • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer • PR Newswire (US) • 07/01/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 06/28/2024 06:00:00 AM
- AbbVie Acquires Celsius Therapeutics • PR Newswire (US) • 06/27/2024 01:26:00 PM
- Introducing Allē Payment Plans, Powered by Cherry • PR Newswire (US) • 06/27/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma • PR Newswire (US) • 06/26/2024 11:03:00 PM
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) • PR Newswire (US) • 06/25/2024 12:15:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 06/21/2024 12:00:00 PM
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors • PR Newswire (US) • 06/20/2024 12:00:00 PM
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease • PR Newswire (US) • 06/18/2024 10:18:00 PM
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer • PR Newswire (US) • 06/14/2024 08:08:00 PM
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease • PR Newswire (US) • 06/13/2024 11:59:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients • PR Newswire (US) • 06/11/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer • PR Newswire (US) • 06/06/2024 12:45:00 PM
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin • PR Newswire (US) • 06/06/2024 12:30:00 PM
- AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers • PR Newswire (US) • 06/06/2024 12:00:00 PM
- AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 • PR Newswire (US) • 06/05/2024 01:00:00 PM
- RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis • PR Newswire (US) • 06/04/2024 12:30:00 PM
- Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 • PR Newswire (US) • 06/04/2024 12:05:00 PM
- AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/03/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:05:10 PM
- AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 05/31/2024 06:00:00 AM
- AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform • PR Newswire (US) • 05/28/2024 12:00:00 PM
- AbbVie Completes Acquisition of Landos Biopharma • PR Newswire (US) • 05/23/2024 08:05:00 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM